Table 5.

Exclusion criteria for trials investigating thromboprophylaxis in PDAC patients.

	FRAGEM Trial [96]	CONKO 004 Trial [97]	CASSINI Trial [122]	AVERT Trial [101]
Thromboprophylaxis	Dalteparin, 200 IU/kg, once daily	Enoxaparin, 1 mg/kg, once daily	Rivaroxaban, 10 mg, once daily	Apixaban, 2.5 mg, twice daily
Exclusion criteria	Karnofsky performance status < 60	Karnofsky performance status < 60	ECOG performance status ≥ 3
		Body weight < 45 kg or > 100 kg		Body weight < 40 kg
	CrCl < 50 mL/min	CrCl < 30 mL/min	CrCl < 30 mL/min	CrCl < 30 mL/min
	• Platelets < 100 × 109/L • Absolute neutrophil count < 2 × 109/L • White cell count < 3 × 109/L • INR > 1.5 • Adequate liver function  Bilirubin > 1.5 upper limit of normal	• Platelets <100 × 109/L • White cell count < 3.5 × 109/L		• Platelets < 50 × 109/L
	• Obvious contraindication to anticoagulation	• Major hemorrhage within the last 2 weeks • Severely impaired coagulation • Active gastrointestinal ulcers  • Major surgery within the last 2 weeks	• Bleeding diathesis • Hemorrhagic lesions • Active bleeding • Conditions with a high risk of bleeding	• Increased risk of significant bleeding • Hepatic disease with coagulopathy
	• Anticoagulation treatment • Antiplatelet treatment (i.e., Aspirin > 75 mg, clopidogrel, etc.)	• Anticoagulation treatment		• Anticoagulation treatment • Medication contraindicated with apixaban

CrCl: creatinine clearance; INR: international normalized ratio; IU/kg: international units/kilogram.